A recent study indicates that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end conventional lifestyle regimens.
Research printed in a prominent medical journal shows that while obese people frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Users using such drugs must be informed of the danger of rapid weight regain when the medication ends," warns researcher Dr. Susan Jebb.
This pace of recovery means a return to starting mass within about one and a half years.
Comparing Therapies
The research, which examined 37 of studies involving thousands of participants, contrasted the results of these new drugs with other pills.
Scientists note that individuals who shed pounds through diet and exercise typically have a less rapid weight regain—approximately 100 grams monthly—once they finish.
Understanding the Fast Regain
Doctors propose the mode of action of the drugs is key to understanding the amplified rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls hunger.
"Artificially providing the hormone concentrations far above than normal may cause the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making binge eating much more probable."
A Chronic Condition?
Health authorities advise the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals contend that, given the high risk of relapse, the therapy is often ongoing.
This view is reinforced by drug manufacturers, who state that the findings "emphasize the persistent nature of excess weight," akin to managing conditions like high blood pressure.
Patient Testimonies
People who have stopped the jabs explain a sudden return of appetite.
"It felt as if something flipping and you're instantly extremely hungry," recalled one woman.
This challenge is compounded if users have not established sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Figures show that a significant number of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is higher among females compared to males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a magic cure and maintained weight loss hinges on ongoing lifestyle management.
